Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

Check out our portfolio of awards below.

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Stanford University Dr. John L. Hennessy Major Facilities Stanford SIM1 Building $43,578,000
Sanford Consortium for Regenerative Medicine Edward Holmes Major Facilities Sanford Consortium for Regenerative Medicine $42,827,439
Buck Institute for Age Research Mary McEachron Major Facilities CIRM Center of Excellence at Buck Institute for Age Research $20,500,000
University of California, Los Angeles Dr. Bennett G Novitch Basic Biology V In vitro modeling of human motor neuron disease $1,148,758
Stanford University Dr. Helen M Blau Basic Biology V Mass Cytometry to Delineate the Human Muscle Stem Cell Hierarchy and Dysfunction in Aging $1,175,357
Stanford University Dr. Marius Wernig MD, PhD Basic Biology V Mechanisms of human induced neuronal cell reprogramming $1,178,370
University of California, Irvine Dr. Peter J Donovan Basic Biology V Non-invasive live imaging of stem cell signature metabolic states $516,366
Palo Alto Veterans Institute for Research Dr. Thomas A. Rando Basic Biology V Molecular regulation of stem cell potency $966,510
University of California, Merced Dr. Kara E McCloskey Basic Biology V Directed Differentiation of Specialized Endothelial Cells $475,686
University of California, San Francisco Dr. Valerie Marie Weaver Basic Biology V Biophysical Determinants of Early Embryonic Stem Cell Fate Specification $1,186,500
California Institute of Technology Dr. David Anthony Tirrell Basic Biology V Engineered matrices for control of lineage commitment in human pancreatic stem cells $526,896
Salk Institute for Biological Studies Ronald Mark Evans Basic Biology V Metabolically-driven epigenetic changes in iPSC reprogramming $1,491,900
University of California, San Diego Dr. Dianne McKay Basic Biology V Role of intracytoplasmic pattern recognition receptors in HSC engraftment $615,639
Stanford University Dr. Gary Steinberg Basic Biology V Paracrine and synaptic mechanisms underlying neural stem cell-mediated stroke recovery $1,178,370
University of California, San Diego Christian Metallo Basic Biology V Metabolic regulation of cardiac differentiation and maturation $1,124,834
University of California, Los Angeles Dr Samantha J Butler Ph.D. Basic Biology V Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate $515,730
Cedars-Sinai Medical Center Paul W Noble Basic Biology V Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man $617,662
Gladstone Institutes, J. David Sheng Ding PhD Basic Biology V A novel druggable mechanism to safeguard stem cell genome $1,294,495
University of California, San Francisco Dr. Mark S. Anderson Basic Biology V Generation of a functional thymus to induce immune tolerance to stem cell derivatives $1,191,000
University of California, Irvine Dr. Lisa A Flanagan Basic Biology V Molecular basis of plasma membrane characteristics reflecting stem cell fate potential $994,108
University of California, San Diego Maike Sander Basic Biology V Defining links between chromatin state and developmental competence $1,050,300
University of Southern California Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $735,138
University of California, Los Angeles Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $411,330
University of California, San Diego Miles F Wilkinson Basic Biology V New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors $552,811
University of California, Los Angeles Dr. Lili Yang Basic Biology V Differentiation of Human Hematopoietic Stem Cells into iNKT Cells $614,400
University of California, San Diego Dr. Cornelis Murre Basic Biology V Epigenetic mechanisms that enforce pluripotency in embryonic stem cells $1,160,997
University of California, San Diego Dr. Wei Wang Basic Biology V Systems-level discovery of the regulatory mechanisms directing differentiation of hESC $1,161,000
University of California, San Diego Dr. Lawrence S. B. Goldstein Basic Biology V Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes $1,050,300
University of California, San Diego Dr. David A. Cheresh Basic Biology V CD61-driven stemness program in epithelial cancer $1,161,000
University of California, Berkeley Dr. Andrew Dillin Basic Biology V A Requirement for Protein Homeostasis in the Mediation of Stem Cell Health $1,034,100
Stanford University Xinnan Wang Basic Biology V Misregulated Mitophagy in Parkinsonian Neurodegeneration $1,174,943
University of Southern California Dr. Mark S Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $16,339,827
University of California, Davis Dr. Peter C. Belafsky Disease Team Therapy Development III Tissue Engineered Recellularized Laryngotracheal Implants $3,181,162
University of California, Los Angeles Dr. Dennis J Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors $5,683,693
Stanford University Professor Irving L Weissman MD Disease Team Therapy Development III Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors $6,505,568
University of California, Los Angeles Dr. Donald B. Kohn PhD Disease Team Therapy Development III Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease $13,145,465
University of California, San Diego Thomas J Kipps Disease Team Therapy Development III Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) $4,179,598
Sangamo BioSciences, Inc. Dr. Fyodor D Urnov Strategic Partnership II A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells $2,760,540
Human BioMolecular Research Institute Dr. John R Cashman Patent Assistance Fund Awards Intellectual Property for Stem Cell-Related Inventions – HBRI $50,000
University of California, San Francisco Karin Immergluck PhD Patent Assistance Fund Awards Patent Assistance Fund Proposal – UCSF $87,257
University of California, Davis David McGee Patent Assistance Fund Awards CIRM Patent Prosecution Assistance Fund for Stem Cell Technologies – UCD $48,595
University of California, Santa Barbara Bernadette McCafferty Patent Assistance Fund Awards Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara. $23,564
University of California, Irvine Ronnie Hanecak Patent Assistance Fund Awards CIRM Patent Assistance Fund Application – UCI $46,155
University of California, Los Angeles Adele Rennie Patent Assistance Fund Awards Patent Assistance Fund – UCLA $84,973
Stanford University Katharine Ku Patent Assistance Fund Awards Funding for Patent Applications for CIRM-funded Inventions out of Stanford University $3,525
University of California, San Diego Dr. Rubén D. Flores Patent Assistance Fund Awards Patent Assistance Fund Application – UCSD $38,162
University of California, San Diego Dr. Lawrence S. B. Goldstein Early Translational from Disease Team Conversion Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $4,139,754
University of California, Los Angeles Dr. Irvin SY Chen Early Translational from Disease Team Conversion Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. $1,505,000
University of California, Los Angeles Dr. Stanley Nelson Early Translational from Disease Team Conversion Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545
University of California, Los Angeles Dr. Robert Reiter MD Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
1 2 3 4 5 6 7 8 9 10 11 12 13 14 … 30

How to Apply

Learn More

Explore CIRM-Funded Clinical Trials

Learn More

Managing Your Grant

Learn More

See our Active Awards Portfolio

Learn More